ClinicalTrials.gg
RecruitingNCT07462507Updated Apr 21, 2026

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

A Phase 2 interventional study of [C-11]-CS1P1 and Brain MRI in Central Nervous System Cancer and Brain Metastases, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Primary conditionBrain NeoplasmsRegistry: Central Nervous System NeoplasmsReclassifiedWhy we changed it
Registry
Central Nervous System Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Brain Neoplasms
Why
  1. The study's listed conditions name Brain Neoplasms, a narrower term within Central Nervous System Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Brain Neoplasms by Washington University School of Medicine — 5 open to participants now, 5 under way, none of them phase 3. Brain Neoplasms · Washington University School of Medicine.

Planned enrollment
Largest of 12
104 · median 20
Started
2026
with 1 other
Phase 2
2 of 14
1 open now
Registered
14th of 14
by date

Among the 14 studies in Brain Neoplasms by Washington University School of Medicine, this one has the largest planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 2, and was the 14th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

5 of the 14 studies in Brain Neoplasms by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Brain Neoplasms by Washington University School of Medicine, or all of them as a file.
02

Study summary

Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline [C-11]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months post-treatment).The study will describe patterns of tracer uptake in tumors and normal brain and explore how these patterns relate to MRI findings, treatments received, and clinical outcomes.

Read the detailed description

This is a prospective, single-arm interventional imaging study designed to evaluate the investigational PET radiotracer [C-11]-CS1P1 in adults with primary or secondary central nervous system malignancies. [C-11]-CS1P1 PET may provide complementary information about disease activity, treatment response, and the tumor microenvironment in central nervous system cancers.

Eligible participants will be adults with confirmed primary central nervous system tumors (for example, gliomas) or secondary central nervous system involvement (brain metastases or other CNS metastases). After providing informed consent, participants will undergo a baseline [C-11]-CS1P1 PET scan in addition to their routine clinical imaging. The PET scan will be performed on a PET/CT or PET/MR scanner following intravenous administration of [C-11]-CS1P1, using a standardized acquisition protocol for brain imaging. Participants will be monitored for adverse events related to tracer administration and radiation exposure, which are expected to remain within accepted research limits.

Participants will be invited to return for one follow-up [C 11]-CS1P1 PET scan within 24 months of the baseline scan, preferably within approximately 6 months after treatment. Follow up imaging will allow assessment of longitudinal changes in [C 11]-CS1P1 uptake in relation to treatment and disease course. Clinical management will not be altered by participation in this study.

Quantitative PET parameters (for example, standardized uptake values, tumor to background ratios, and volumetric measures) will be derived from tumor and normal appearing brain. Qualitative assessments of tracer uptake patterns will also be performed. These PET measures will be compared with MRI characteristics, treatment history, and available clinical outcomes (including radiographic progression and survival) to explore the potential of [C 11]-CS1P1 PET as a diagnostic biomarker of tumor activity and treatment response in central nervous system malignancies. This exploratory study is intended to generate preliminary data that may inform the design of future trials using [C 11]-CS1P1 PET in this patient population.

03

Conditions studied

  • Central Nervous System Cancer
  • Brain Metastases

Keywords

  • Primary brain tumor
  • Glioma
  • Glioblastoma
  • Astrocytoma
  • Oligodendroglioma
  • Brain metastasis
04

In context

Brain Neoplasms Reclassified

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

This study's planned enrollment of 104 is above the median of 40 across 1,838 interventional studies indexed under Brain Neoplasms.

Browse Brain Neoplasms studies →

Lead sponsor

Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.

Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.

Compared within Brain Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Central Nervous System Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, any race
  • Age ≥ 18 years
  • Capable of providing written OR having a legally authorized representative (LAR) to provide informed consent for volunteering to undergo research procedure
  • Has a clinical, radiographic, or pathological diagnosis of primary or secondary CNS that has not been treated with radiotherapy

Exclusion criteria

Exclusion Criteria:

  • to [C-11]-CS1P1 or any of its
  • to PET, CT or MRI (e.g. certain incompatible electronic medical devices, inability to lie still for extended periods) that make it potentially unsafe for the individual to participate
  • Prior cranial radiotherapy
  • Severe claustrophobia that would require general anesthesia
  • Women who are currently pregnant or breastfeeding
  • Any condition that, in the opinion of the Sponsor-Investigator or designee could increase risk to the participant, limit the participant's ability to tolerate the research procedures or interfere with the collection of the data (e.g., advanced renal or liver failure)
  • Current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the U.S. Code of Federal Regulations (CFR) Title 21 Section 361.1. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=361.1.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    [C-11]-CS1P1 PET

    C-11\]-CS1P1 PET image acquisition up to 90 minutes will be acquired at baseline and at follow-up visit within 24 months (preferably within 6 months post treatment), along with an optional brain MRI.

    Drug: [C-11]-CS1P1 · Device: Brain MRI

Interventions

  • Drug[C-11]-CS1P1

    * The investigational radiotracer \[C-11\]-CS1P1 is an S1P1 PET imaging agent. * The PET imaging will be acquired either in a PET/MR scanner or the PET/CT scanner

  • DeviceBrain MRI

    Optional

07

What researchers measure

Primary outcomes

  1. [C-11]CS1P1 Standardized uptake value (SUV) ratio of tumor to non-tumor regions of interest (ROIs)

    \[C-11\]CS1P1-SUV ratio at the baseline and associated 95% confidence interval (CI) will be calculated.

    Time frame: Baseline

Secondary outcomes

  1. Follow-up changes from the baseline in [C-11]CS1P1 SUV ratio

    \[C-11\]CS1P1-SUV ratio at the follow up scan and change from the baseline as well as their associated 95% confidence interval (CI) will be calculated.

    Time frame: Baseline and 24 months

  2. Number of participants with adverse events

    Measured and graded per CTCAE v 6.0.

    Time frame: From time of scan through 2-3 days

08

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Tammie L.S. Benzinger, M.D., Ph.D. · Contactbenzingert@wustl.edu · 314-362-1558
    • Jayashree Rajamanickam · Contactjayashree.r@wustl.edu · 314-273-6140
    • Tammie L.S. Benzinger, M.D., Ph.D. · Principal investigator
    • Hongyu An, Ph.D. · Sub investigator
    • G. Richard Benzinger, M.D., Ph.D. · Sub investigator
    • Matthew R Brier, M.D., Ph.D. · Sub investigator
    • Yong Wang, Ph.D. · Sub investigator
    • Qing Wang, Ph.D. · Sub investigator
    • Jiayi Huang, M.D. · Sub investigator
    • Zhude Tu, Ph.D. · Sub investigator
    • Richard Laforest, Ph.D. · Sub investigator
    • C. Ryan King, M.D., Ph.D. · Sub investigator
    • Esther Lu, Ph.D. · Sub investigator
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2031, 62 months after the start.

Of 208 non-industry phase 2 interventional studies under Brain Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 100. This study's planned 62 months is close to that.

Counting every sponsor, half of 252 studies reached it within 61 months; a quarter within 38 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 10, 2026
StartActual
Apr 16, 2026
Primary completionEst.
Jun 30, 2031
CompletionEst.
Jun 30, 2033
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07462507
Responsible party
Sponsor
First posted
Mar 10, 2026
Start date
Apr 16, 2026
Primary completion
Jun 30, 2031 (estimated)
Completion
Jun 30, 2033 (estimated)
Last update
Apr 21, 2026

Study contacts

Tammie L.S. Benzinger, M.D., Ph.D.
Contact
benzingert@wustl.edu
314-362-6110
Jayashree Rajamanickam
Contact
jayashree.r@wustl.edu
314-273-6140
Tammie L.S. Benzinger, M.D., Ph.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion